CN106619754A - Medicine compound for treating glaucoma - Google Patents
Medicine compound for treating glaucoma Download PDFInfo
- Publication number
- CN106619754A CN106619754A CN201611133171.7A CN201611133171A CN106619754A CN 106619754 A CN106619754 A CN 106619754A CN 201611133171 A CN201611133171 A CN 201611133171A CN 106619754 A CN106619754 A CN 106619754A
- Authority
- CN
- China
- Prior art keywords
- ethanol
- extract
- pharmaceutical composition
- weight
- percent concentration
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Withdrawn
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
- A61K31/58—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids containing heterocyclic rings, e.g. danazol, stanozolol, pancuronium or digitogenin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2236/00—Isolation or extraction methods of medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicine
- A61K2236/30—Extraction of the material
- A61K2236/33—Extraction of the material involving extraction with hydrophilic solvents, e.g. lower alcohols, esters or ketones
- A61K2236/333—Extraction of the material involving extraction with hydrophilic solvents, e.g. lower alcohols, esters or ketones using mixed solvents, e.g. 70% EtOH
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2236/00—Isolation or extraction methods of medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicine
- A61K2236/30—Extraction of the material
- A61K2236/39—Complex extraction schemes, e.g. fractionation or repeated extraction steps
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2236/00—Isolation or extraction methods of medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicine
- A61K2236/50—Methods involving additional extraction steps
- A61K2236/51—Concentration or drying of the extract, e.g. Lyophilisation, freeze-drying or spray-drying
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2236/00—Isolation or extraction methods of medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicine
- A61K2236/50—Methods involving additional extraction steps
- A61K2236/55—Liquid-liquid separation; Phase separation
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Natural Medicines & Medicinal Plants (AREA)
- Public Health (AREA)
- Chemical & Material Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Veterinary Medicine (AREA)
- Epidemiology (AREA)
- Engineering & Computer Science (AREA)
- Alternative & Traditional Medicine (AREA)
- Biotechnology (AREA)
- Botany (AREA)
- Medical Informatics (AREA)
- Microbiology (AREA)
- Mycology (AREA)
- Medicines Containing Plant Substances (AREA)
Abstract
The invention discloses a medicine compound for treating glaucoma and a preparation method thereof. The medicine compound disclosed by the invention is prepared from the bulk drugs, including sisalagenin, gomphandra tetrandra and willowweed. The medicine compound can be prepared into various preparations according to a conventional preparation technology and is effective in treating glaucoma.
Description
Technical field
The invention belongs to technical field of traditional Chinese medicines, more particularly to a kind of pharmaceutical composition for treating glaucoma and its preparation side
Method.
Background technology
Primary glaucoma is current main diseases causing blindness, and some areas are only second to cataract and occupy second.But
From unlike cataract, the visual function damage of glaucoma is usually irreversible.Therefore, how preferably to protect glaucoma patient
Visual function, be the key for ensureing and improving glaucoma patient quality of life from now on.Glaucoma belongs to traditional Chinese medical science glaucoma and blue or green wind
Cataract or glaucoma category, is qi-blood disharmony by the cause such as irritability stasis, spleen humidogene phlegm, liver and gall heated, hyperactivity of yang due to yin deficiency, and passages through which vital energy circulates is unfavorable, profound in mesh
Mansion is inaccessible, refreshing water alluvial, leads to this disease.It can be seen that, train of thought stasis, sweat pore obstruction, refreshing water alluvial are the total interpretation of the cause, onset and process of an illness of glaucoma, all the time
During the entire process of being applied in glaucoma.In recent years research shows that intraocular pressure is not that primary open-angle glaucoma visual function is damaged
Still there is the progressive injury of visual function in harmful single factor, the patient that some intraocular pressures have been controlled.Therefore, glaucoma visual function is damaged
Evil is multifactor property, and it is clearly inadequate clinically to have focused solely on reduction intraocular pressure to the treatment of glaucoma in the past.Some scholars
It was found that patients with primary open-angle glaucoma has the blood supply that blood viscosity increases and affect optic disk and retina, can cause
Or the visual function damage of quickening glaucoma.
Sisalagenin（Tigogenin）：CAS 77-60-1, molecular formula C27H44O3, molecular weight 416.64.【Biology is living
Property】The raw material of synthetic hormone.【Ingredient origin】Sisal hemp Agave sisalana.
Black bone is galloped along on horseback：This product is that Icacinaceae must stamen fogfruit crin wood Gomphandra tetrandra（Wall.et
Roxb.）Sleum ［ Lasian theratetrandra Wall.et Roxb.；Gomphandra hainanensis Merr. ］
Root.Whole year can excavate, and clean, and section is dried.【Nature and flavor】It is bitter；It is flat.【Indication】Clearing away damp-heat；Relieving heat toxin.Master is damp and hot
Vomit and diarrhoea；Carbuncle sore tumefacting virus.【Former phytomorph】Crin wood shrub or dungarunga, high 2-10m.Bark grey, spray green, then
Raw branch is become without hair later by pubescence.Leaf alternate, the long 0.5-1.5cm of petiole, just by pubescence；Leaf papery, narrow lanceolar, length
Oval or oblong, long 6-15cm, wide 2-6cm, tip is tapering, base portion wedge shape, full edge, two sides without hair or during children below quilt
Faint yellow pubescence, above it is dark green, below slightly weaker, middle arteries overleaf significant protuberance, lateral vein about 6-8 pair, net vein is not obvious.Male and female
Different strain, cyme and leaf opposite, armpit life sometimes, long 2-4cm is close by yellow-white pubescence, has common peduncle, the long 0.2- of bennet
0.5cm；Male flower yellow-white or white green, 5 numbers are about 5mm, and corolla is bell, long 3-4mm, the nearly triangle of petal sliver, and length is about
The 1/3 of corolla, inward curl, outside is without hair；Stamen 4-5, filigree is longer than corolla；Female flower yellow-white, is about 5mm, calyx micro- 5
Split, it is long less than 5mm；Corolla is bell, is about 0.5mm, and petal sliver Yangtze River Delta shape is curved in tip；Obsolete stamen in female flower
Isometric with ovary, ovary is cylindric, and without hair or sometimes by hair, column cap is little, 5 split it is slightly downward in ovary.Drupe is oval, is about
1.2-2.5cm, footpath 0.5-1.2cm, white when ripe, berry shape has obvious vertical rib after doing, and carpopodium is slightly by pubescence.Flower, fruiting period
It is annual.Record in dictionary of medicinal plant.
Willowweed：The herb of Oenotheraceae Epilobium plant willowweed Epilobium hirsutum L..It is annual
Adopt, dry.【Nature and flavor】Bitter；It is light；It is cold in nature.【Indication】It is clearing heat and detoxicating；Dampness removing antidiarrheal；Help digestion qi-regulating；Promoting blood circulation synthetism.Master is wet
Hot rush down dysentery；Dyspepsia；Abdominal distention；Toothache；Irregular menstruation；Amenorrhea；Under band；Injury and bone fracture；Sore swells；Burn and scald；Scabies.【Chemistry
Composition】Willowweed aerial part (gallic acid) containing gallic acid, 3- methoxyl group gallic acid (3-methoxygallic
Acid), protocatechuic acid (Protocatechuic acid) and hyperin (hyperoside).In addition this product also contains Kaempferol
(kaemp ferol), Quercetin (quercetin), myricetin (myricetin), Quercetin -3-O- β-D- glucopyras
Glucoside (quercetin-3-O- β-D-glucopyranoside), myricetin rutinoside (myricetin
) and different valonie acid (isovalonic acid) rubinoside.Additionally, leaf and flower also contain palmitic acid (palmitic
Acid), stearic acid (stearic acid), linoleic acid (linoleic acid), oleanolic acid (oleanolic acid), mountain
Short, bristly hair or beard acid (crategolic acid), tormentic acid (tormentic acid), arjunolic acid (arjunolic acid) and
23- hydroxyl tormentic acids (23-hydroxytormentic acid).【Pharmacological action】Leaf, in vitro to staphylococcus aureus
There is inhibitory action, poisoning can occur epileptiform convulsion with stupor.Record in dictionary of medicinal plant.
1 bulk drug chemical constitution：
Sisalagenin（Tigogenin）.
The content of the invention
The purpose of the present invention is to overcome the shortcomings of background technology, there is provided a kind of pharmaceutical composition of effectively treatment glaucoma and
Its preparation method.
The present invention adopts the following technical scheme that realization：
The composition and weight portion for making the bulk drug of the pharmaceutical composition of the treatment glaucoma be：
Sisalagenin 26-30 weight portion black bones are galloped along on horseback 1280-1290 weight portion willowweed 840-846 weight portions.
The pharmaceutical composition for the treatment of glaucoma is preferably used in, is made up of the bulk drug of following weight portion：
The weight portion black bone of Sisalagenin 28 is galloped along on horseback the weight portion of 1285 weight portion willowweed 843.
A kind of pharmaceutical composition for treating glaucoma, it is characterised in that pharmaceutical composition can adopt the routine side of galenic pharmacy
Method prepares piece agent or capsule or dripping pill.
A kind of pharmaceutical composition for treating glaucoma, it is characterised in that pharmaceutical composition and controlling that chemical drugs or Chinese medicine are constituted
Treat glaucoma medicine.
A kind of preparation method of the pharmaceutical composition for treating glaucoma, it is characterised in that prepare as follows：
The composition and weight portion of bulk drug be：Sisalagenin 26-30 weight portion black bones are galloped along on horseback 1280-1290 weight portion willow leaves
Dish 840-846 weight portions；
Preparation method：
（1）By bulk drug proportioning take Sisalagenin, black bone gallop along on horseback, willowweed, mix, with the ethanol of weight percent concentration 33%
As solvent, take in 25.5 DEG C of temperature extractions, extraction time is 14 times, and each extraction time is 10 hours, and each solvent load is
52 times of bulk drug gross weight, filtration obtains dregs of a decoction A and extract A, and extract A reclaims ethanol, is concentrated into relative density 1.15,
Filtration, liquid is first washed with water by XAD-12 large pore resin absorption columns, then is washed with the ethanol solution of weight percent concentration 14%
De- XAD-12 large pore resin absorption columns, collect the ethanol eluate of weight percent concentration 14%, reclaim ethanol, and concentrate drying is obtained final product
Extract A；
（2）Take step（1）Dregs of a decoction A, with the ethanol of weight percent concentration 52% as solvent, heating and refluxing extraction 18 times, carries every time
The time is taken for 0.7 hour, each solvent load is 12 times of dregs of a decoction A weight, filters, obtain dregs of a decoction B and extract B, extract B is returned
Ethanol is received, relative density 1.12 is concentrated into, is filtered, liquid is first washed with water by DA-201 large pore resin absorption columns, then with again
Amount percent concentration 73% ethanol solution wash-out DA-201 large pore resin absorption columns, collect the ethanol elution of weight percent concentration 73%
Liquid, reclaims ethanol, and concentrate drying obtains final product extract B；
（3）Extract A and extract B are mixed, pharmaceutical composition is obtained final product.
Preferred a kind of preparation method of the pharmaceutical composition for treating glaucoma, it is characterised in that prepare as follows：
The composition and weight portion of bulk drug be：The weight portion black bone of Sisalagenin 28 is galloped along on horseback the weight of 1285 weight portion willowweed 843
Amount part；
Preparation method：
（1）By bulk drug proportioning take Sisalagenin, black bone gallop along on horseback, willowweed, mix, with the ethanol of weight percent concentration 33%
As solvent, take in 25.5 DEG C of temperature extractions, extraction time is 14 times, and each extraction time is 10 hours, and each solvent load is
52 times of bulk drug gross weight, filtration obtains dregs of a decoction A and extract A, and extract A reclaims ethanol, is concentrated into relative density 1.15,
Filtration, liquid is first washed with water by XAD-12 large pore resin absorption columns, then is washed with the ethanol solution of weight percent concentration 14%
De- XAD-12 large pore resin absorption columns, collect the ethanol eluate of weight percent concentration 14%, reclaim ethanol, and concentrate drying is obtained final product
Extract A；
（2）Take step（1）Dregs of a decoction A, with the ethanol of weight percent concentration 52% as solvent, heating and refluxing extraction 18 times, carries every time
The time is taken for 0.7 hour, each solvent load is 12 times of dregs of a decoction A weight, filters, obtain dregs of a decoction B and extract B, extract B is returned
Ethanol is received, relative density 1.12 is concentrated into, is filtered, liquid is first washed with water by DA-201 large pore resin absorption columns, then with again
Amount percent concentration 73% ethanol solution wash-out DA-201 large pore resin absorption columns, collect the ethanol elution of weight percent concentration 73%
Liquid, reclaims ethanol, and concentrate drying obtains final product extract B；
（3）Extract A and extract B are mixed, pharmaceutical composition is obtained final product.
A kind of preparation method of the pharmaceutical composition for treating glaucoma, it is characterised in that pharmaceutical composition can adopt preparation
Conventional method prepares piece agent or capsule or dripping pill.
A kind of preparation method of the pharmaceutical composition for treating glaucoma, it is characterised in that pharmaceutical composition and chemical drugs or in
Medicine composition treatment glaucoma medicine.
Medicine composite for curing glaucoma is evident in efficacy.
Specific embodiment
Embodiment 1：Pharmaceutical composition for the treatment of glaucoma and preparation method thereof
Treatment glaucoma pharmaceutical composition bulk drug composition and weight portion be：Sisalagenin 28g black bones are galloped along on horseback
1285g willowweed 843g；
Preparation method：
（1）By bulk drug proportioning take Sisalagenin, black bone gallop along on horseback, willowweed, mix, with the ethanol of weight percent concentration 33%
As solvent, take in 25.5 DEG C of temperature extractions, extraction time is 14 times, and each extraction time is 10 hours, and each solvent load is
52 times of bulk drug gross weight, filtration obtains dregs of a decoction A and extract A, and extract A reclaims ethanol, is concentrated into relative density 1.15,
Filtration, liquid is first washed with water by XAD-12 large pore resin absorption columns, then is washed with the ethanol solution of weight percent concentration 14%
De- XAD-12 large pore resin absorption columns, collect the ethanol eluate of weight percent concentration 14%, reclaim ethanol, and concentrate drying is obtained final product
Extract A；
（2）Take step（1）Dregs of a decoction A, with the ethanol of weight percent concentration 52% as solvent, heating and refluxing extraction 18 times, carries every time
The time is taken for 0.7 hour, each solvent load is 12 times of dregs of a decoction A weight, filters, obtain dregs of a decoction B and extract B, extract B is returned
Ethanol is received, relative density 1.12 is concentrated into, is filtered, liquid is first washed with water by DA-201 large pore resin absorption columns, then with again
Amount percent concentration 73% ethanol solution wash-out DA-201 large pore resin absorption columns, collect the ethanol elution of weight percent concentration 73%
Liquid, reclaims ethanol, and concentrate drying obtains final product extract B；
（3）Extract A and extract B are mixed, pharmaceutical composition is obtained final product.
Embodiment 2：Pharmaceutical composition for the treatment of glaucoma and preparation method thereof
Treatment glaucoma pharmaceutical composition bulk drug composition and weight portion be：Sisalagenin 26g black bones are galloped along on horseback
1290g willowweed 840g；
Preparation method：
（1）By bulk drug proportioning take Sisalagenin, black bone gallop along on horseback, willowweed, mix, with the ethanol of weight percent concentration 33%
As solvent, take in 25.5 DEG C of temperature extractions, extraction time is 14 times, and each extraction time is 10 hours, and each solvent load is
52 times of bulk drug gross weight, filtration obtains dregs of a decoction A and extract A, and extract A reclaims ethanol, is concentrated into relative density 1.15,
Filtration, liquid is first washed with water by XAD-12 large pore resin absorption columns, then is washed with the ethanol solution of weight percent concentration 14%
De- XAD-12 large pore resin absorption columns, collect the ethanol eluate of weight percent concentration 14%, reclaim ethanol, and concentrate drying is obtained final product
Extract A；
（2）Take step（1）Dregs of a decoction A, with the ethanol of weight percent concentration 52% as solvent, heating and refluxing extraction 18 times, carries every time
The time is taken for 0.7 hour, each solvent load is 12 times of dregs of a decoction A weight, filters, obtain dregs of a decoction B and extract B, extract B is returned
Ethanol is received, relative density 1.12 is concentrated into, is filtered, liquid is first washed with water by DA-201 large pore resin absorption columns, then with again
Amount percent concentration 73% ethanol solution wash-out DA-201 large pore resin absorption columns, collect the ethanol elution of weight percent concentration 73%
Liquid, reclaims ethanol, and concentrate drying obtains final product extract B；
（3）Extract A and extract B are mixed, pharmaceutical composition is obtained final product.
Embodiment 3：Pharmaceutical composition for the treatment of glaucoma and preparation method thereof
Treatment glaucoma pharmaceutical composition bulk drug composition and weight portion be：Sisalagenin 30g black bones are galloped along on horseback
1280g willowweed 846g；
Preparation method：
（1）By bulk drug proportioning take Sisalagenin, black bone gallop along on horseback, willowweed, mix, with the ethanol of weight percent concentration 33%
As solvent, take in 25.5 DEG C of temperature extractions, extraction time is 14 times, and each extraction time is 10 hours, and each solvent load is
52 times of bulk drug gross weight, filtration obtains dregs of a decoction A and extract A, and extract A reclaims ethanol, is concentrated into relative density 1.15,
Filtration, liquid is first washed with water by XAD-12 large pore resin absorption columns, then is washed with the ethanol solution of weight percent concentration 14%
De- XAD-12 large pore resin absorption columns, collect the ethanol eluate of weight percent concentration 14%, reclaim ethanol, and concentrate drying is obtained final product
Extract A；
（2）Take step（1）Dregs of a decoction A, with the ethanol of weight percent concentration 52% as solvent, heating and refluxing extraction 18 times, carries every time
The time is taken for 0.7 hour, each solvent load is 12 times of dregs of a decoction A weight, filters, obtain dregs of a decoction B and extract B, extract B is returned
Ethanol is received, relative density 1.12 is concentrated into, is filtered, liquid is first washed with water by DA-201 large pore resin absorption columns, then with again
Amount percent concentration 73% ethanol solution wash-out DA-201 large pore resin absorption columns, collect the ethanol elution of weight percent concentration 73%
Liquid, reclaims ethanol, and concentrate drying obtains final product extract B；
（3）Extract A and extract B are mixed, pharmaceutical composition is obtained final product.
Embodiment 4：The preparation of tablet
The pharmaceutical composition 274g of Example 1, adds starch 262, mixes, and granulation is dried, plus microcrystalline cellulose 165g, stearic
Sour magnesium 3g, mixes, and is pressed into 1300, obtains final product medicinal composition tablets.
Embodiment 5：The preparation of capsule
The pharmaceutical composition 216g of Example 2, adds starch 180g, mixes, and granulation is dried, whole grain, adds appropriate stearic acid
Magnesium, mixes, and encapsulated 700, obtains final product medicament composition capsule.
Embodiment 6：The preparation of dripping pill
Weigh (80 DEG C) heating of Macrogol 6000 245g water-baths and boil molten, add the pharmaceutical composition 11g of embodiment 3, fully stir
Mix uniform, with atoleine as cooling agent, put glass tube（4*80cm）In, chilling temperature is 5 DEG C, and drip internal-and external diameter is 7.0/
2.0 (mm/mm), drip is 2.2cm away from liquid level, and drop speed, as optimum condition, with cotton the cold of dripping pill surface is blotted with per point 47 drops
Solidifying agent, obtains final product medicament composition dropping pills.
Experimental example 1：The experimental study for the treatment of glaucoma
1 materials and methods
1.1 ordinary circumstance
Observation Endothelium in Patients with Primary Glaucoma 28 50, wherein male 14 25, female 14 25；It is the oldest 72 years old, minimum
18 years old, average 56 years old.All cases are city's hospital ophthalmology inpatient.
1.2 packet situations
Case is divided into by conventional therapy group and pharmaceutical composition group, wherein conventional therapy group man 7, female 7 according to medicining condition；
It is the oldest 72 years old, minimum 18 years old, average 58 years old；Type of glaucoma closes angle person 12, angle of release 2；Mean vision before treatment
0.45, average intraocular pressure 3.65kPa.Pharmaceutical composition group man 7, female 7；It is the oldest 71 years old, minimum 19 years old, average 55 years old；
Type of glaucoma closes angle person 11, angle of release 3；Mean vision 0.50 before treatment, average intraocular pressure 4.11kPa.
1.3 treatment method
Conventional therapy group:Using conventional, intraocular pressure treatment method, including medicine (hypertonic dehydration profit, aqueous humor generation suppression are dropped
Agent, miotic etc.) and operation (trabeculectomy, peripheral iridectomy).
Pharmaceutical composition group:While using conventional drop intraocular pressure treatment method, combination of oral medication（The medicine of embodiment 1
Composition）, each 1.5g 2 times a day, continuously takes 20 days.
Eye test:Carried out under identical inspection environment with same international standard visual chart.
2 results
Eyesight improves 14 (56.00%) after the treatment of conventional therapy group, and eyesight improves 23 after the treatment of pharmaceutical composition group
(92.00%), two groups of Different therapeutical effects have conspicuousness (P<0.05) (it is shown in Table 1).
The comparitive study with conventional therapy promoting blood circulation and removing blood stasis of table 1
Statistical method:Rank test；P<0.05.
Claims (8)
1. a kind of pharmaceutical composition for treating glaucoma, it is characterised in that make the composition and weight of the bulk drug of the pharmaceutical composition
Measuring part is：
Sisalagenin 26-30 weight portion black bones are galloped along on horseback 1280-1290 weight portion willowweed 840-846 weight portions.
2. a kind of pharmaceutical composition for treating glaucoma according to claim 1, it is characterised in that make the pharmaceutical composition
Bulk drug composition and weight portion be：
The weight portion black bone of Sisalagenin 28 is galloped along on horseback the weight portion of 1285 weight portion willowweed 843.
3. a kind of pharmaceutical composition for treating glaucoma according to claim 1, it is characterised in that pharmaceutical composition can be adopted
Piece agent or capsule or dripping pill are prepared with the conventional method of galenic pharmacy.
4. a kind of pharmaceutical composition for treating glaucoma according to claim 1, it is characterised in that pharmaceutical composition and chemistry
The treatment glaucoma medicine of medicine or Chinese medicine composition.
5. a kind of preparation method of the pharmaceutical composition for treating glaucoma, it is characterised in that prepare as follows：
The composition and weight portion of bulk drug be：Sisalagenin 26-30 weight portion black bones are galloped along on horseback 1280-1290 weight portion willow leaves
Dish 840-846 weight portions；
Preparation method：
（1）By bulk drug proportioning take Sisalagenin, black bone gallop along on horseback, willowweed, mix, with the ethanol of weight percent concentration 33%
As solvent, take in 25.5 DEG C of temperature extractions, extraction time is 14 times, and each extraction time is 10 hours, and each solvent load is
52 times of bulk drug gross weight, filtration obtains dregs of a decoction A and extract A, and extract A reclaims ethanol, is concentrated into relative density 1.15,
Filtration, liquid is first washed with water by XAD-12 large pore resin absorption columns, then is washed with the ethanol solution of weight percent concentration 14%
De- XAD-12 large pore resin absorption columns, collect the ethanol eluate of weight percent concentration 14%, reclaim ethanol, and concentrate drying is obtained final product
Extract A；
（2）Take step（1）Dregs of a decoction A, with the ethanol of weight percent concentration 52% as solvent, heating and refluxing extraction 18 times, carries every time
The time is taken for 0.7 hour, each solvent load is 12 times of dregs of a decoction A weight, filters, obtain dregs of a decoction B and extract B, extract B is returned
Ethanol is received, relative density 1.12 is concentrated into, is filtered, liquid is first washed with water by DA-201 large pore resin absorption columns, then with again
Amount percent concentration 73% ethanol solution wash-out DA-201 large pore resin absorption columns, collect the ethanol elution of weight percent concentration 73%
Liquid, reclaims ethanol, and concentrate drying obtains final product extract B；
（3）Extract A and extract B are mixed, pharmaceutical composition is obtained final product.
6. a kind of preparation method of the pharmaceutical composition for treating glaucoma according to claim 5, it is characterised in that by as follows
It is prepared by step：
The composition and weight portion of bulk drug be：The weight portion black bone of Sisalagenin 28 is galloped along on horseback the weight of 1285 weight portion willowweed 843
Amount part；
Preparation method：
（1）By bulk drug proportioning take Sisalagenin, black bone gallop along on horseback, willowweed, mix, with the ethanol of weight percent concentration 33%
As solvent, take in 25.5 DEG C of temperature extractions, extraction time is 14 times, and each extraction time is 10 hours, and each solvent load is
52 times of bulk drug gross weight, filtration obtains dregs of a decoction A and extract A, and extract A reclaims ethanol, is concentrated into relative density 1.15,
Filtration, liquid is first washed with water by XAD-12 large pore resin absorption columns, then is washed with the ethanol solution of weight percent concentration 14%
De- XAD-12 large pore resin absorption columns, collect the ethanol eluate of weight percent concentration 14%, reclaim ethanol, and concentrate drying is obtained final product
Extract A；
（2）Take step（1）Dregs of a decoction A, with the ethanol of weight percent concentration 52% as solvent, heating and refluxing extraction 18 times, carries every time
The time is taken for 0.7 hour, each solvent load is 12 times of dregs of a decoction A weight, filters, obtain dregs of a decoction B and extract B, extract B is returned
Ethanol is received, relative density 1.12 is concentrated into, is filtered, liquid is first washed with water by DA-201 large pore resin absorption columns, then with again
Amount percent concentration 73% ethanol solution wash-out DA-201 large pore resin absorption columns, collect the ethanol elution of weight percent concentration 73%
Liquid, reclaims ethanol, and concentrate drying obtains final product extract B；
（3）Extract A and extract B are mixed, pharmaceutical composition is obtained final product.
7. a kind of preparation method of the pharmaceutical composition for treating glaucoma according to claim 5, it is characterised in that medicine group
Compound can adopt the conventional method of galenic pharmacy to prepare piece agent or capsule or dripping pill.
8. a kind of preparation method of the pharmaceutical composition for treating glaucoma according to claim 5, it is characterised in that medicine group
Compound and chemical drugs or Chinese medicine composition treatment glaucoma medicine.
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN201611133171.7A CN106619754A (en) | 2016-12-10 | 2016-12-10 | Medicine compound for treating glaucoma |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN201611133171.7A CN106619754A (en) | 2016-12-10 | 2016-12-10 | Medicine compound for treating glaucoma |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| CN106619754A true CN106619754A (en) | 2017-05-10 |
Family
ID=58825854
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CN201611133171.7A Withdrawn CN106619754A (en) | 2016-12-10 | 2016-12-10 | Medicine compound for treating glaucoma |
Country Status (1)
| Country | Link |
|---|---|
| CN (1) | CN106619754A (en) |
-
2016
- 2016-12-10 CN CN201611133171.7A patent/CN106619754A/en not_active Withdrawn
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CN106619754A (en) | Medicine compound for treating glaucoma | |
| CN104523962A (en) | Radix morindae officinalis health maintenance traditional Chinese medicine wine and preparation method | |
| CN104547494A (en) | Traditional Chinese medicine composition medicinal liquor for treating hyperthyroidism and preparation process | |
| CN106619816A (en) | Pharmaceutical composition for treating optic atrophy | |
| CN106668125A (en) | Pharmaceutical composition for treating optic atrophy and preparation method of pharmaceutical composition | |
| CN106620056A (en) | Pharmaceutical composition for treating diabetic retinopathy | |
| CN106539934A (en) | A kind of pharmaceutical composition for treating optic atrophy | |
| CN106109927A (en) | A kind of pharmaceutical composition treating chloasma and preparation method thereof | |
| CN106539838A (en) | Prevent and treat the pharmaceutical composition of neurodermatitis | |
| CN106728407A (en) | A kind of pharmaceutical composition for treating glaucoma | |
| CN106727844A (en) | Treat the pharmaceutical composition of insomnia | |
| CN106728128A (en) | Prevent and treat the pharmaceutical composition of glaucoma | |
| CN102670957A (en) | Health-care composition and preparation method and application thereof | |
| CN106729031A (en) | A kind of pharmaceutical composition for treating cold in children | |
| CN106540027A (en) | It is a kind of to prevent and treat pharmaceutical composition of laryngitis and preparation method thereof | |
| CN106540090A (en) | Prevent and treat pharmaceutical composition of optic atrophy and preparation method thereof | |
| CN106727756A (en) | It is a kind of to treat pharmaceutical composition of glaucoma and preparation method thereof | |
| CN106511545A (en) | Medicinal composition for treating vitreous opacity | |
| CN106728473A (en) | A kind of pharmaceutical composition for preventing and treating diabetic retinopathy | |
| CN106581222A (en) | Pharmaceutical composition for treating suspension of vitreous body | |
| CN106668543A (en) | Medicinal composition for preventing and treating cervicitis and preparation method thereof | |
| CN106822261A (en) | Prevent and treat pharmaceutical composition of neurodermatitis and preparation method thereof | |
| CN106668336A (en) | Pharmaceutical composition for treating otitis media | |
| CN106728143A (en) | Prevent and treat pharmaceutical composition of vitreous opacity and preparation method thereof | |
| CN106728475A (en) | Prevent and treat pharmaceutical composition of diabetic retinopathy and preparation method thereof |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| PB01 | Publication | ||
| PB01 | Publication | ||
| SE01 | Entry into force of request for substantive examination | ||
| SE01 | Entry into force of request for substantive examination | ||
| WW01 | Invention patent application withdrawn after publication | ||
| WW01 | Invention patent application withdrawn after publication |
Application publication date: 20170510 |